Infrequent Resolution of Vaso‐Occlusive Crises in Routine Clinical Care Among Patients Mimicking the Exa‐Cel Trial Population: A Cohort Study of Medicaid Enrollees
Clinical Pharmacology & Therapeutics · 2024
DOI: 10.1002/cpt.3449 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Clinical Pharmacology & Therapeutics, 2024. Verfasst von Mufaddal Mahesri und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital & Harvard Medical School, Boston, Massac…. Hauptthemen laut MEDLINE: Medicaid, Anemia, Sickle Cell. Die Arbeit nennt 32 Literaturangaben. Gefördert von: Vertex Pharmaceuticals Incorporated.
Abstract (Originalsprache)
The CRISPR‐based gene editing therapy exagamglogene autotemcel (exa‐cel) recently received FDA approval for patients with severe sickle cell disease (SCD). The approval was based on a phase III trial (CLIMB SCD 121), which showed 97% efficacy of this treatment in eliminating vaso occlusive crises (VOCs) for 12 consecutive months. To help contextualize results from this trial, we aimed to investigate the proportion of patients with severe SCD who remain VOC‐free for a 1‐year period in routine clinical care. Using Medicaid claims data (2000–2018), we identified a cohort of patients, 12–35 years old with severe SCD, defined by ≥ 2 VOCs per year for 2 consecutive years, who met other exa‐cel trial inclusion criteria to mimic a trial‐like population. A VOC was identified using ICD diagnosis codes during hospitalization and ER visits. The primary outcome was the proportion of patients with no VOCs during a 1‐year follow‐up. A total of 7,425 patients with severe SCD [mean (SD) age: 20.5 (6.0) years, 54.6% females, 84% African Americans], had a mean of 5.2 VOCs, 5.1 ER visits and 3.5 hospitalizations per year during the baseline period. The proportion of patients with no VOCs during the 1‐year follow‐up was 7.7% (95% confidence interval: 7.1%–8.3%). In conclusion, less than one in 12 patients with severe SCD achieved VOC‐free status within 1 year in routine clinical care. These findings suggest that the high efficacy observed for exa‐cel in the trial, if replicated in routine clinical care, could translate into a significant public health impact.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital & Harvard Medical School, Boston, Massachusetts, USA.
- Vertex Pharmaceuticals Inc., Boston, Massachusetts, USA.
- Epi Excellence LLC, Garnet Valley, Pennsylvania, USA.
ORCID-Profile: Mufaddal Mahesri, Su Been Lee, Timothy Beukelman, Lina Titievsky, Rishi J Desai
Förderung
- Vertex Pharmaceuticals Incorporated
Zitieren
APA
Mahesri, M., Lee, S. B., Levin, R., Imren, S., Zhang, L., Beukelman, T., Titievsky, L., & Desai, R. J. (2024). Infrequent Resolution of Vaso‐Occlusive Crises in Routine Clinical Care Among Patients Mimicking the Exa‐Cel Trial Population: A Cohort Study of Medicaid Enrollees. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3449
Vancouver
Mahesri M, Lee SB, Levin R, Imren S, Zhang L, Beukelman T, et al. Infrequent Resolution of Vaso‐Occlusive Crises in Routine Clinical Care Among Patients Mimicking the Exa‐Cel Trial Population: A Cohort Study of Medicaid Enrollees. Clinical Pharmacology & Therapeutics. 2024. doi:10.1002/cpt.3449
BibTeX
@article{Mahesri2024,
author = {Mahesri, Mufaddal and Lee, Su Been and Levin, Raisa and Imren, Suzan and Zhang, Lanju and Beukelman, Timothy and Titievsky, Lina and Desai, Rishi J},
title = {Infrequent Resolution of Vaso‐Occlusive Crises in Routine Clinical Care Among Patients Mimicking the Exa‐Cel Trial Population: A Cohort Study of Medicaid Enrollees},
journal = {Clinical Pharmacology & Therapeutics},
year = {2024},
doi = {10.1002/cpt.3449}
}
EUVIMED